Can Ozempic Cause Retinal Hemorrhage?
Yes, Ozempic (semaglutide) is associated with diabetic retinopathy complications including retinal hemorrhage, particularly in patients with pre-existing diabetic retinopathy or those experiencing rapid glucose reduction. The FDA label explicitly warns about diabetic retinopathy complications, and recent evidence confirms associations with retinal hemorrhage among other retinal adverse events 1.
Understanding the Risk
The mechanism appears dual:
- Rapid glucose reduction effect: When A1C drops quickly (a known effect of semaglutide), temporary worsening of diabetic retinopathy can occur—a phenomenon previously documented with intensive insulin therapy 2, 3
- Direct retinal complications: The SUSTAIN 6 trial demonstrated that 3.0% of semaglutide-treated patients experienced diabetic retinopathy complications versus 1.8% on placebo. The absolute risk was substantially higher (8.2% vs 5.2%) in patients with baseline diabetic retinopathy 1
Recent pharmacovigilance data strengthens these concerns. A 2025 global analysis of over 76,000 cases found semaglutide significantly associated with retinal/vitreous hemorrhage (ROR = 2.44-5.89 in FAERS, ROR = 5.49-20.91 in VigiBase compared to metformin) 4. Another 2025 study specifically identified retinal hemorrhage as more frequently reported with subcutaneous semaglutide formulations 5.
Clinical Algorithm for Safe Use
Before initiating Ozempic:
- Assess retinopathy status - Obtain dilated comprehensive eye examination if not done within past year 2
- Identify high-risk patients: Those with known diabetic retinopathy, especially proliferative disease, or baseline A1C >10% with long diabetes duration
- Document baseline A1C to anticipate degree of glucose reduction
During treatment:
- Monitor vision changes actively - Instruct patients to report any visual changes immediately 1
- Increase ophthalmology surveillance - Patients with baseline retinopathy require more frequent eye exams (at minimum annually, potentially every 3-6 months if retinopathy present) 2
- Titrate gradually in high-risk patients to minimize rapid A1C drops, though this must be balanced against cardiovascular benefits
If retinopathy worsens:
The 2024 ADA guidelines explicitly state: "Retinopathy status should be assessed when intensifying glucose-lowering therapies such as those using GLP-1 RAs, since rapid reductions in A1C can be associated with initial worsening of retinopathy" 2. However, guidelines emphasize that long-term glycemic control benefits outweigh acute risks 3.
Critical Nuances
The evidence presents an important paradox: While semaglutide can acutely worsen retinopathy through rapid glucose reduction, long-term glycemic control ultimately protects against retinopathy progression 2. The 2022 Canadian guidelines note: "The long-term benefits of glucose control on the eyes far outweigh any acute risk" 3.
Distinguishing from aspirin: Unlike concerns about antiplatelet therapy, aspirin does NOT increase retinal hemorrhage risk and should not be discontinued 6, 7, 8. This is an important clinical distinction.
Formulation matters: Subcutaneous semaglutide shows higher reporting rates for retinal complications compared to oral formulations, though both carry risk 5.
Common Pitfalls to Avoid
- Don't skip baseline eye exams - The absolute risk increase is 3-fold higher in patients with pre-existing retinopathy who aren't being monitored 1
- Don't confuse correlation with contraindication - Pre-existing retinopathy is NOT a contraindication to semaglutide; it's an indication for closer monitoring 2, 3
- Don't attribute all retinal hemorrhage to the drug - Diabetic retinopathy naturally progresses; the drug may accelerate existing disease rather than cause de novo hemorrhage in patients without diabetes-related eye disease
- Don't discontinue without ophthalmology input - If retinopathy worsens, coordinate with ophthalmology for potential laser photocoagulation or anti-VEGF therapy rather than automatically stopping a medication with proven cardiovascular mortality benefit 2, 1
Bottom line for practice: Ozempic can cause retinal hemorrhage as part of diabetic retinopathy complications. Screen eyes before starting, monitor vision during treatment, and increase ophthalmology surveillance in patients with baseline retinopathy—but don't withhold this cardiovascular-protective medication based solely on retinopathy presence.